Amarin Corporation plc (ADR) (NASDAQ: AMRN) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced a clinical update that’s leading to excitement among investors who are pushing the stock toward the top. Today, we’ll talk about the update, what we’re seeing from AMRN as a result, and what we’ll be watching for ahead.
AMRN Gains On Clinical Update
As mentioned above, Amarin Corporation is having a strong start to the trading session this morning after issuing a press release early this morning with regard to a key clinical trial. The data surrounded the REDUCE-IT cardiovascular outcomes study. In the release, AMRN announced that the study has reported and documented more than 90% of the targeted 1,612 primary major adverse cardiovascular events.